Vishal Sikka’s resignation from Infosys comes at a time when recession’s looming large over the IT sector. With promoters on one side and the governing body on the other, it’s the employees’ morale that’s on the backburner, not to mention stakeholders and the public at large who begin to wonder why dirty linen is being openly washed. Narayana Murthy’s comment that Sikka is not CEO material doesn’t speak well, especially when it’s the board that appointed him. There’s no point crying over spilt milk.

Ashok Jayaram

Bengaluru

Sikka’s resignation is unfortunate. No doubt, it is the culmination of continuous allegations made by founder Narayana Murthy over the issues of corporate governance and salary increases to Sikka and other top executives in the company. Under Sikka’s stewardship Infosys has seen a stupendous transformation, thanks to his unbridled commitment to company’s growth through innovation, enabled by education. As a man known for a passion for technology, he has left a strong imprint on Infosys by turning its focus on transformative technologies like AI.. His exit is a worrisome development.

M Jeyaram

Sholavandan, Tamilnadu

Clear picture

‘Do we really need retail quotas in IPOs?’ by Aarati Krishnan captures the pulse of retail investors. Investing philosophy to an extent can also be based on the past performance of a company, but this is completely non-existent in the case of IPOs. Retail investors unlike the institutional ones neither have a risk management framework to apply, nor the time to scrutinise or gauge the performance of IPOs. Jumping on the band-wagon to get a pie-in-the-sky with hard earned money is a bad illustration of success in the case of IPOs.

Magesh Lakshmi

Bengaluru

Affordable at last

It is heartening to see that the price of knee surgery will be brought down; drug price regulators have fixed the prices of knee implants between ₹54,000 and ₹1.14 lakh. Earlier the government had curbed the price of cardiac stents. Private hospitals and medical colleges might suffer losses now, but this step will make transplants affordable.

Bal Govind

Noida, Uttar Pradesh

Unfair pricing policy

Pharma pricing not only needs to be aligned with the notions of ‘ease of doing business’ and ‘Make in India’ but should also reckon with the pricing policies and the interests of the and senior citizens. The arbitrary pricing of medical products is very exploitative and too serious to be ignored.

If a healthcare corporate or hospital is doing very well and adds considerable value to the existing wealth of shareholders, it is definitely at the cost of consumers, the large patient populace. An ambitious pricing policy adopted for drugs paved way for huge profits by charging consumers heavily. This is not a healthy business model for a developing country. Why shouldn’t prices be based on cost plus profit up to a certain limit? Cost needs to be properly arrived at without padding up, but duly cost audited. Only this can ensure equitable distribution of business values among consumers and manufacturers.

RS Raghavan

Bengaluru

Why the delay?

The Tamil Nadu CM’s announcement that the State government will constitute a commission to probe former Chief Minister J Jayalalithaa’s death is a belated move. The announcement that Jayalalithaa’s Poes Garden residence would be converted into a memorial should also be well received. With two prime conditions set by the rival faction led by O Panneerselvam being met, the prospect of a merger in the AIADMK appears bright.

NJ Ravi Chander

Bengaluru

Too little, too late

The Supreme Court’s question — “Who made and supplied bomb to kill Rajiv?” — comes 25 years after the event. The judicial process is so slow that people are losing faith in the judiciary.

S Ramakrishnasayee

Ranipet, Tamil Nadu

Related Topics
comment COMMENT NOW